Author: Editor

R. Houston Thompson, MD of the Mayo Clinic presents NCCN and AUA GUIDELINES FOR RCC: DO THEY EFFECTIVELY CAPTURE RECURRENCES FOLLOWING NEPHRECTOMY? at the Kidney Cancer Association meeting in Chicago 2014

Joel Prince of The University of Wisconsin School of Medicine and Public Health presents Patient and Tumor Characteristics Predict Indeterminate Renal Mass Biopsy Findings

Jose A. Karam, MD Assistant Professor Department of Urology MD Anderson presents Locally Advanced RCC: Neoadjuvant Targeted Therapy

Tony Finelli MD, MSc, FRCSC GU Site Lead, Princess Margaret Cancer Center GU Lead, Cancer Care Ontario Associate Professor, University of Toronto presents Quality Indicators in Kidney Cancer Care at the Kidney Cancer Assoication meeting in Chicago 2014

Lara Barbara – Breast Cancer Survivor NSHOA Treats Patients with Chemo and Hugs brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Michael Murray – Primary Goal for Everyone at NSHOA is Patient Care brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)         medical oncology, nshoa, the community oncology alliance (coa), coa, the coa patient advocacy network (cpan), cpan

Dr. Ron Burkes commenting on the results of the Lux-Lung8 Trial from ESMO 2014

Dr. Natasha Leighl, lead study author, on the newsiest results on the activity of pembrolizumab in lung cancer

Dr. Edith Perez speaking on the expanded results of the ALTTO breast cancer trial

Dr. Sunil Verma providing a comprehensive update on the latest lung cancer updates from ESMO 2014

Don Marx – Care for Today, Research for Tomorrow brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Dr. Tewari at ESMO 2014 on latest advanced cervical cancer therapies

Dr. Teresa Petrella and Dr. Catalin Mihalcioiu speaking on combination therapies in melanoma.

Mark Levine – CFO North Shore Hematology Oncology Focused on Patient Care brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Immuno-Oncology: Shaping the Present, Transforming the Future and Raising the Bar in Oncology – from Best of ASCO Canada 2014

Nicole Gregory – The Chief Commercial Officer – What we do for our Patients brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Michael Mitrani – Guiding Patients Through the Benefits Maze brought to you by The Community Oncology Alliance (COA) and The COA Patient Advocacy Network (CPAN)

Timothy A. Masterson, MD Assistant ProfessorDepartment of UrologyIndiana University Medical Center and Vitaly Margulis MD Associate Professor of Urology of UT Southern Medical Center debate the Debate: Partial Nephrectomy v. RADICALNephrectomy for T1b/2a tumors

Nicholas G. Cost, M.D.Assistant Professor, Department of Surgery, Division of Urology University of Colorado School of Medicine discusses Hereditary Syndromes in Kidney Cancer: Beyond VHL at the Kidney Cancer Association meeting in Chicago

Brian Shuch, MD Assistant Professor of Urology and Radiology Yale School of Medicine presents Management of Kidney Cancer in Young Patients at the Kidney Cancer Association meeting in Chicago

E. Jason Abel MD, FACS of the University of Wisconsin presents Renal mass biopsy for risk stratification in RCC: benefits and limitations at the Kidney Cancer Association meeting in Chicago.

Mark Purdue, PhDOntario Institute for Cancer Research discusses Epidemiology and Genomics of Renal Cell Carcinoma at the Kidney Cancer Association meeting in Chicago

Projecting Individual Probability for Developing Renal Cell Cancer presented by Xifeng Wu, MD, PHD, Professor and ChairDepartment of Epidemiology Betty B. Marcus Chair in Cancer Prevention Director, Center for Translational and Public Health Genomics at the annual Kidney Cancer Association meeting in 2014

At the iwNHL 2014, Dr Rafael Fonseca (Mayo Clinic, Arizona, USA) interviews Prof Keith Stewart (Mayo Clinic, Arizona, USA) and Prof Leif Bergsagel (Mayo Clinic, Arizona, USA), all doctors with an interest in myeloma, about the application of myeloma biology and therapies in lymphoma. Prof Stewart describes tumour heterogeneity and suggests a parallel between myeloma and indolent follicular lymphoma, where the presence of a more aggressive tumour subclone may have significant clinical implications. Prof Bergsagel describes the contribution of MYC to tumour heterogeneity and poor prognosis. Targeting the interaction between the immune system and tumour may provide new therapies.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Wolfram Brugger (University of Freiburg, Villingen-Schwenningen, Germany) and Dr Myron Czuczman (Roswell Park Cancer Institute, New York, USA) about the current and future clinical application of targeted or chemotherapy-free therapies in lymphoma. They discuss their experiences and some of the challenges of these therapies in clinical practice. It is emphasised that targeted therapies should not necessarily be used as standalone approaches. Combinations of targeted therapies and conventional therapies should be considered, and emerging clinical trials investigating combinations are described. The use of patient’s age to determine…

At the iwNHL 2014, Dr Steven Rosen (City of Hope National Medical Center, California, USA) describes the progress made in understanding the biology and management of non-Hodgkin lymphoma. Now, there is need to consider new drug combinations to maximise efficacy. Alternatives to chemotherapy including biologic approaches and future research directions including in precision medicine are examined.

At the iwNHL 2014, Dr Mathias Rummel (Justus-Liebig University-Hospital, Gießen, Germany) describes his research investigating the use of bendamustine plus rituximab in treating indolent and mantle-cell lymphomas, highlighting the clinical implications of his long-term findings. He also presents an overview of the progress in other treatment strategies. He concludes with a description of the current and prospective treatment strategies for indolent lymphomas.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy. Understanding the biology of the lymphoma microenvironment may allow rational therapeutic targeting. Emerging clinical studies in this field are reviewed. The immune system is presented as a potential and attractive target to disrupt the interaction between the tumour and non-tumour microenvironment cells, with a focus on lenalidomide and rituximab immunotherapy.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy. Improved trial designs, consideration of clinical variables and use of higher resolution approaches are recommended to overcome current research limitations in this field.

At the iwNHL 2014, Prof John Gribben (Barts Cancer Institute, London, UK) interviews Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada) about the significance of the lymphoma microenvironment in tumour biology and therapy. The interaction between tumour cells and non-tumour cells has been increasingly recognised to contribute to disease progression.

Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA), Prof Anton Hagenbeek (Academic Medical Center, Amsterdam, Netherlands), Prof Michael Pfreundschuh (University of Saarland, Homburg-Saar, Germany) and Dr Myron Czuczman (Roswell Park Cancer Institute, Buffalo, USA) about the highlights from day two of the 12th iwNHL. The group discusses the value of a multidisciplinary approach in cancer management. Understanding of myeloma biology and therapies is proposed to be applicable to NHL; specifically, there is an emerging paradigm of tumour subclones that facilitate drug resistance. Implications of investigational lymphoma therapies are…

Prof John Gribben (Barts Cancer Institute, London, UK) chairs a discussion with Prof Randy Gascoyne (British Columbia Cancer Agency, Vancouver, Canada), Dr Wyndham Wilson (National Cancer Institute, Bethesda, USA) and Dr Myron Czuczman (Roswell Park Cancer Institute, Buffalo, USA) about the highlights from day one of the 12th iwNHL. There is an increasing recognition of the lymphoma microenvironment in influencing tumour progression and clinical outcomes. In peripheral T-cell lymphomas, progress in understanding the interaction between tumour cells of origin and non-tumour cells may allow rational and novel therapeutic targeting. Future treatment options for patients with diffuse large B-cell lymphoma who…

At the iwNHL 2014, Prof Michael Pfreundschuh (Saarland University Medical School, Homburg, Germany), Dr Rich Fisher (Fox Chase Cancer Center, Pennsylvania, USA) and Prof Christian Gisselbrecht (Hôpital Saint-Louis, Paris, France) discuss the biology and management of diffuse large B-cell lymphoma (DLBCL). Dr Fisher describes the difficulties in defining and managing patients who are not cured by standard therapy. The classification of DLBCLs is an important consideration for research studies and clinical management. Double-hit lymphomas have poor prognosis and management options are discussed. Prof Gisselbrecht describes important recent advances in treatment options for different DLBCL subtypes. Future research directions and their…

At the iwNHL 2014, Prof Susan OBrien (MD Anderson Cancer Center, Texas, USA) and Prof Eva Kimby (Karolinska Institutet, Huddinge, Sweden) provide an overview of mantle cell lymphoma. Current treatment strategies are discussed. There is a focus on ibrutinib therapy for patients who relapse after first-line therapy and a comparison is made with its use in treating chronic lymphocytic leukaemia. Future trial and clinical directions are also examined.

At ESMO 2014, Dr Jennifer Temel is interviewed about the results of a phase III trial investigating the use of anamorelin in NSCLC patients with anorexia and cachexia. She discusses the next steps for anamorelin with a focus on regulatory approval and impact in clinical practice.

At ESMO 2014, Prof Tony Mok presents the results of the IMPRESS trial. This phase III trial showed that continuation of gefitinib with chemotherapy versus chemotherapy alone provided no significant improvement in progression-free survival in patients with EGFR mutation-positive lung cancer who previously failed to respond to first-line gefitinib.

At ESMO 2014, Prof Sandra Swain presents the results of the CLEOPATRA trial. This phase III trial in patients with HER2-positive metastatic breast cancer showed that treatment with pertuzumab combined with trastuzumab plus docetaxel (pertuzumab group) significantly improved overall survival versus placebo combined with trastuzumab plus docetaxel treatment (control group). Median overall survival in the pertuzumab group was increased by 15.7 months versus the control group.

During a press conference at ESMO 2014, Prof Frédéric Amant, University of Leuven, Leuven, Belgium, discusses his study on the impacts of mental and cardiac development in children who are exposed to chemotherapy or radiotherapy while in the womb.

At ESMO 2014, Prof Johan F. Vansteenkiste summarises the results of the MAGRIT trial, a phase III trial which showed that MAGE-A3 cancer immunotherapy did not increase disease-free survival in patients with resected NSCLC.

During a press conference at ESMO 2014, Dr Jean-Pascal Machiels, Cliniques Universitaires St. Luc, Brussels, Belgium, presents the results of a Phase III study looking at the impact of afatinib versus methotrexate upon progression-free survival in patients with head and neck cancer after failure of platinum-based chemotherapy.

During a press conference at ESMO 2014, Dr Bernardo Leon Rapoport, The Medical Oncology Centre Rosebank, Johannesburg, South Africa, presents the results of a Phase III study on the use of rolapitant for the prevention of chemotherapy-induced nausea and vomiting in patients receiving cisplatin-based chemotherapy.

During the Saturday press conference at ESMO 2014, Professor David Currow describes results of Phase III data showing that a new drug, anamorelin, improves appetite and body mass in patients with advanced lung cancer, who are suffering cancer anorexia and cachexia. In the ROMANA studies, patients with unresectable stage III or IV non-small cell lung cancer with cachexia were randomized to receive either 100 mg anamorelin or placebo, given orally each day for 12 weeks. For those patients taking anamorelin, lean body mass and body weight were significantly increased. Professor Currow mentions that patients did not experience improvements in their…

Results of the MPACT Trial (weekly nab-paclitaxel plus gemcitabine versus gemcitabine alone) in patients with metastatic pancreatic cancer will be reviewed, with emphasis on patient selection and neuropathy management. The webinar was delivered by Dr. Malcolm Moore, Program Head, Medical Oncology and Hematology, Director, McCain Centre for Pancreatic Cancer; Professor, Department of Medicine and Pharmacology, University of Toronto.

The objective of this webinar was to provide an overview of the available front-line therapeutic options for patients with metastatic pancreatic cancer and compare the relative effectiveness and potential side effect profiles of different chemotherapeutic regimens.

A study published online in the August 2014 edition of the Annals of Surgical Oncology shows that BluePrint (Agendia Inc) proves to be superior to conventional subtyping for analyzing breast cancer before surgery. [1] The study, which will also be published in the October print edition of the journal, is part of the ongoing Neoadjuvant Breast Registry Symphony Trial (NBRST, pronounced “N-breast”).[2][3] These finding may eventually change the way physicians evaluate and treat breast cancer. The researchers concluded that the BluePrint genomic test provides more accurate information about the molecular subtype of a specific breast cancer, compared to the use…

Tamoxifen (Soltamox/Nolvadex®; AstraZeneca), an antagonist of the estrogen receptor ? in ER?-positive breast cancer has been effective in most patients. The drug has been used for more than 40 years to treat breast cancers that are hormone-receptor positive. As an adjuvant therapy tamoxifen improves overall survival. Its widespread use is thought to have made a significant contribution to the reduction in breast cancer mortality seen over the last decade. [1] However, resistance to tamoxifen is a clinically significant problem. So far, the mechanisms responsible for tamoxifen resistance remain elusive. Results from a study funded by the Dutch Cancer Society (KWF)…

The immune system has the ability to recognize tumors and to stop or control their development through a process known as immunosurveillance. The PD-1 checkpoint pathway plays a key role in modulating the immune system. This video describes how tumor cells exploit the PD-1 checkpoint pathway and evade the immune response, leading to tumor growth. Immuno-oncology

For more free video updates go to www.oncologyeducation.com Incorporation of Bv into anthracycline and taxane containing adjuvant therapy does not improve IDFS or OS in pts with high risk HER2- breast cancer. Bv did increase AEs but no unexpected AEs were encountered. Longer duration therapy is unlikely to be feasible given the high rate of early discontinuation due to all causes.

To view more free videos – visit www.oncologyeducation.com Profiling of protein expression, gene copy variations and mutations identified clinically relevant alterations in 99% of sarcomas. Given the overexpression of TOPO2 in approximately 50% of sarcomas, its utility as a biomarker of sensitivity to anthracyclines should be studied, especially in relation to TP53 status in a tumor. Trials of agents like mTOR and PI3K inhibitors could benefit from designs in which patient selection is based on PTEN loss or PIK3CA mutations instead of sarcoma histology. The prognostic implications of the co-existence of TP53 mutations and PTEN loss in sarcomas is yet…

For additional free GI/Colorectal Cancer video updates, please go to www.oncologyeducation.com Chemo/CET and chemo/BV equivalent in OS in pts KRAS wt (codons 12 + 13) MCRC; either is appropriate in first line. Overall OS of 29 + mos and 8% long-term survivors confirms progress in MCRC. The preference for FOLFOX limits chemotherapy comparison. Expanded RAS and other molecular and clinical analyses may identify subsets of pts who get more or less benefit from specific regimens.

Dr Kenneth Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK) and Prof Paul Richardson (Harvard Medical School, Boston, USA) at Myeloma 2014 about the treatment of myeloma. They discuss the trends in therapy they expect to see in the next decade and provide a response to the definitions workshop.

Dr Anderson (Dana Farber Cancer Institute, Boston, USA) chairs a discussion with Prof Palumbo (University of Torina, Torina, Italy), Prof Gareth Morgan (The Royal Marsden Hospital, London, UK), and Prof San Miguel (University Hospital, Salamanca, Spain) at Myeloma 2014 about the treatment of Myeloma. They discuss novel targets and the treatment of high risk disease, and immune based therapy, and provide new insights in drug sensitivity and resistance.

Prof Keith Stewart (Mayo Clinic, Scottsdale, USA) chairs a discussion with Prof Gareth Morgan (The Royal Marsden Hospital, London, UK), Dr Leif L. Bergsagel (Mayo Clinic, Scottsdale, Arizona), and Prof Antonio Palumbo (University of Torina, Torina, Italy) at Myeloma 2014, about the treatment of myeloma. They discuss the clinical implications and strategies to overcome clonal heterogeneity, genomics and practice, early treatment, immune based therapy, and new insights in IMiD drug sensitivity and resistance.

Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, tells the European Medical Journal about the possible enormous value of minimal residual disease (MRD) monitoring in multiple myeloma (MM) as a potential new end-point in MM clinical trials, and as a marker of therapeutic response.

Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older patients .

Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, summarises recent plethora of data in patients with newly diagnosed myeloma. A key recent advance is to treat patients more aggressively earlier with three drug combinations. He outlines latest views on MRD (minimal residual disease), and highlights the promising findings in older patients .

Dr Ola Landgren from Memorial Sloan Kettering, New York, USA, speaks to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting about the changed definition of multiple myeloma. A result of a 2-day workshop of the international myeloma working group before the EHA meeting, the definition now includes three additional criteria which are explained. Dr Landgren explores the reason for the altered definition and implications for clinical practice.

Speaking to the European Medical Journal from the 19th Congress of the European Haematology Association (EHA) meeting, Prof. John Seymour from Sir Peter MacCallum, Department of Oncology, Australia, outlines the three presentations at the meeting updating clinicians on the latest findings with ABT199 , an investigational B-cell lymphoma 2 (BCL-2) selective inhibitor. Firstly, he outlines the results from the monotherapy dose-escalation study, which has completed recruitment (n=105) and shown positive clinical findings. Secondly , he summarises the findings from the step-wise programme developed to avoid tumour lysis syndrome with ABT199. Thirdly , Prof. Seymour discusses the promising early data from…

Dr Kenneth Anderson, Multiple Myeloma Boston 2014 congress round-up

Prof. Peter Hillmen from Leeds Teaching Hospital, Leeds, UK, gives an update on the phase III results from the RESONATE study in 391 patients with relapsed refractory chronic lymphoid leukemia (CLL). Prof Hillmen outlines the PFS and OS results that showed the significant benefits of ibrutinib over ofatumumab. He comments on single vs. combination therapy with ibrutinib in CLL.

Speaking to EMJ from the 19th Congress of the European Hematology Association (EHA 19) meeting, Prof. Paul Richardson , Dana-Farber Cancer Institute, USA, discusses results seen from the breakthrough PANORAMA1 study, a global randomised, double-blind, placebo-controlled phase III study of panobinostat in combination with bortezomib and dexamethasone in patients with relapsed multiple myeloma. He outlines the primary end-point results and side effects observed, and comments on the clinical meaningfulness of these HDAC trial results. Results of sub-sets of higher risk groups are also discussed, and Prof Richardson comments on new data with ricolinostat (ACY-1215) in multiple myeloma. Keywords: EMJ Relapsed…

Prof. Simon Rule from Plymouth Hospital, UK, discusses data presented at EHA19 on the second-generation oral BTK inhibitor, ONO-4059. One study presented relates to CLL; the other to non-Hodgkins lymphoma (NHL). In both studies, ONO-4059 shows promising results that might allow it to compete with ibrutinib. He also outlines the benefits seen with ibrutinib in several haematological cancers, and a poster showing two-year ibrutinib toxicity data.

Prof. Valeria Santini, University of Florence Medical School, Italy, highlights novel mutational and genetic studies in MDS presented atEHA19 which might in the future translate into clinical benefits. One involves a significantly sensitive and sophisticated prognostic scoring system; another involves gene expression in MDS that may allow the classification of patients according to prognosis. Keywords: Myelodysplastic Syndrome (MDS) Prof. Valeria Santini University of Florence Medical School Genetic studies in MDS EHA19

Prof. Stephan Stilgenbauer from University of Ulm, Germany, defines ultra high-risk CLL (chronic lymphocytic leukemia) and comments on its implications for patients. He outlines highlights from ASCO 2014 and EHA 2014 in CLL, addressing the latest data with ibrutinib from the RESONATE trial, and on resistance issues observed with ibrutinib. He also comments on the use of single vs. combination agents in CLL – including new treatments such as ibrutinib, idelalisib, and ABT199. Keywords: EMJ Ultra high-risk CLL Ibrutinib Prof. Stephan Stilgenbauer University of Ulm Chronic Lymphocytic Leukemia (CLL) ASCO 2014 EHA 2014 RESONATE trial Ibrutinib Idelalisib ABT199

Held annually in South Florida every January, The Symposium on Clinical Interventional Oncology (CIO) features a concentrated 2-day program renowned for its originality, patient-care focus and dynamic learning format. CIO focuses on highlighting the most viable and sought-after treatments in interventional oncology while shining a spotlight on current best practices and previewing developments on the horizon. CIO is the must-attend symposiumof the year for IO novices and expert learners searching to stay on the brink of innovation of contemporary techniques, methodologies and technological advances. Join your peers and attend North Americas fastest growing meeting in the IO arena. We look…

When it comes to EGFR and lung cancer, is a mutation good or bad? Dr. Joel Neal of Stanford University Medical Center explains why non-mutated genes are called “wild type.” February 2014.

Prof David Cameron from The Edinburgh Cancer Research Centre is committed to identifying potential new approaches to treating and preventing breast cancer. We caught up with him at EBCC9 in Glasgow to find out what’s new for breast cancer patients. He tells us about ongoing research as well as some of the findings that were being presented at the congress.

A retrospective study of the effect of extending mammography to age 75 was performed in the Netherlands to use data emerging from the change of policy shifting age-based mammography to 75 in 1999. More early stage tumours were detected but just as many cases of late-stage disease were discovered as before, implying that screening had not eliminated them and was not yielding a benefit. Further analysis confirmed that the harmful effects of over-treatment in this age group were outweighing any potential benefits of cancer detection. Dr. Liefers concluded that age-based screening is failing these patients who should receive mammography on…

A detailed analysis of risk factors including genomic markers of women with breast cancer has revealed that three-year mammographic screening is insufficient for around half of all women who could be candidates for annual screening. This is good news for regions where annual screening is the norm as it suggests a potential saving by screening less frequently in one subgroup, but perhaps less welcome news in countries such as the UK where three-year screening is recommended.

A massive Oxford meta-analysis they have completed has shown that adjuvant radiotherapy gives absolute benefits in terms of progression-free and overall- survival in women with breast cancer who have one, two, or three involved axillary lymph nodes clarifying a long-held uncertainty. Up to now four or more nodes has been a status known to benefit from R/T, while node-zero did not confer any benefit from R/T. The effect is surprisingly large and is just as strong among women who received either chemotherapy or endocrine therapy extending considerably the application of adjuvant radiotherapy.

Dr Poortmans presented a late breaking abstract at a workshop on the regional control of breast cancer, along with speakers from Denmark, Canada and the UK. His abstract was on the updated results of his groups EORTC ROG and BCG phase III trial22922/10925 confirming the benefits of chest irradiation for patients with early breast cancer irrespective of their axillary nodal status. One of the key new points the data were presently able to confirm was that such regional radiotherapy extends life not only in chemotherapy-naïve patients, but also in those who have received extensive systemic therapy.

Dr. Mark Socinski is a Professor of Medicine, University of Pittsburgh School of Medicine. In this video, he answers common questions about the role of the PD-1 checkpoint pathway in normal immune function and tumor immune evasion.

7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

Gestione degli effetti collaterali delle terapie e delle complicanze post-chirurgiche 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna, 29-03-2014

Stato dell’arte e ricerca clinica attuale (SECONDA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo 2014

Il percorso della ricerca nei GIST in laboratorio. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

Caso clinico 3: terapia con Regorafenib in terza linea di trattamento. 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

Don Sharpe talks to Terri Guidi, MBA of Oncology Management and Consulting about a real life case study of an analysis of oncology practice value to the hospital.

Don Sharpe sits down with Ted Okon the Executive Director of The Community Oncology Alliance and they talk about what’s impacting cancer care at the COA annual meeting.

Don Sharpe talks to Ricky Newton, CPA of Cancer Specialists of Tidewater about how to understand the business issue of quality cancer care. The interview was presented at COA annual meeting.

Don Sharpe talks to Dr. Jeff Vacirca, MD of North Shore Hematology and Oncology concerning the Effects of Sequestration to Community Oncologists.

Don Sharpe of OBR interviews Dr. Ira Klein, MD where he asks What is Gene Forward and Gene Backward?

Don Sharpe sits down with Dr. Brian Van Tine, MD PhD or Washington University to talk about Management and Treatment of Sarcoma.

Don Sharpe discusses the Payer Perspective on Molecular Testing with Dr. Micheal Kolodziej, MD from Aetna at the COA annual meeting.

Don Sharpe of OBR talks about the variances in genetic testing and how that may affect health care decisions with Dr. Lee Newcomer, MD of UnitedHealthCare.

Don Sharpe talks about Molecular Testing for Cancer from a Payer Perspective with Dr. Sundeep Reddy, MD (Caris Life Sciences) at the COA annual meeting.

Don Sharpe of OBR discusses the topic What’s Making Your Oncologist Sick? with Dr. Joseph Lynch, MD at the COA annual meeting.

Don Sharpe talks to Rebecca Bechhold, MD about Integrating Palliative Care and Oncology from the COA annual meeting in Orlando.

Don Sharpe of OBR discusses The Genetic Science Behind Heredity Colon Cancer Syndromes with Dr. Larry Geier, MD at the COA annual meeting.

Don Sharpe of OBR discusses The Medical Home past and future with Bo Gamble, Director of Strategic Practice Initiatives, Community Oncology Alliance.

Don Sharpe of OBR discusses how an oncology practice get’s started with The Medical Home model and the implemenation process with Carol Murtaugh, RN, OCN of Hematology & Oncology Consultants. Interview conducted at the annual COA meeting in Orlando, FL.

Don Sharpe of OBR discusses the progress for payers who are using The Medical Home model with Gordon Kuntz of ION Solutions at the annual COA meeting in Orlando, FL.

Don Sharpe of OBR talks to Dr. Daniel McKeller, MD of the Commission on Cancer about the report on The Medical Home. The interview was at COA annual meeting.

Don Sharpe talks to Stuart Genschaw, Exec. Dir. of Cancer & Hematology Centers of Western Michigan about innovation within oncology payment reforms from the COA annual meeting.

Don Sharpe asks the question Why are you embracing payment reform at The Center for Cancer and Blood Disorders to Barry Russon, CEO. Community Oncology Alliance annual meeting.

Don Sharpe discusses the success at Advanced Medical Specialties using Accountable Care Organization (ACO) with Dr. Leonard Kalman, MD from the annual COA meeting.

Don Sharpe talks to Dr. Barbara McAneny, MD from New Mexico Cancer Center about the CMMI Award and setting up The Medical Home at the COA meeting in Orlando.

Don Sharpe talks about the importance of cancer patient advocacy from the point of view of a medical oncologists Dr. Erin Dunbar, MD of Piedmont Healthcare.

Don Sharpe discusses Dr Erin Dunbar, MD or Piedmont Healthcare her presentation entitled “Good News from the Oncologist” at the COA annual meeting.

Don Sharpe of OBR talks to Dr. Lucio Gordon, MD of Florida Cancer Specialists about the role of IT, Electronic Medical Records, and Big Data in the future for oncology.

Don Sharpe talks to Angel Aslo, PharmD about the role of in house pharmacies within the community oncology setting.

Don Sharpe discusses with Ray Bailey, PharmD the role in which in house pharmacies play within oncology practices.

Don Sharpe of OBR discusses a surprise announcement from Dr. Siddhartha Mukherjee author and Pulitzer prize winner for The Emperor of All Maladies: A Biography of Cancer

Don Sharpe of OBR discusses molecular profiling with Dr. John Powderly of Carolina BioOncology Institute at COA.

Don Sharpe discusses with Ray Bailey, PharmD the role in which in house pharmacies play within oncology practices.

Don Sharpe of OBR discusses a surprise announcement from Dr. Siddhartha Mukherjee author and Pulitzer prize winner for The Emperor of All Maladies: A Biography of Cancer

Don Sharpe of OBR discusses molecular profiling with Dr. John Powderly of Carolina BioOncology Institute at COA.

Stato dell’arte e ricerca clinica attuale (PRIMA PARTE) 7 ° Riunione Nazionale AIG Associazione Italiana GIST Onlus Bologna 29 marzo 2014

7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014

Terapia Sunitinib: verso la personalizzazione della cura. 7° Riunione Annuale A.I.G. Associazione Italiana GIST Onlus, Bologna 29 marzo 2014

Dott. Paolo G. Casali, Responsabile SSD Oncologia Medica Tumori Mesenchimali dell’Adulto, Fondazione IRCCS Istituto Nazionale Tumori – Milano 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014

Messaggio dell’Associazione e Introduzione ai lavori 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna 29 marzo 2014

Imatininb nella terapia pre-operatoria, adiuvante e di prima linea nel trattamento del GIST 7° Riunione Nazionale A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

Benvenuto e introduzione 7° Riunione Nazionale di A.I.G. Associazione Italiana GIST Onlus Bologna, 29 marzo 2014

SAN FRANCISCOThe ability of cancer cells to evolve clonally into molecularly distinct strands needs to be considered when selecting targeted therapies to treat renal cancer, according to Dr Tom Powles MBBS, MRCP, MD speaking at the ASCO GU Cancers Symposium here. Dr Tomasz Beer, MD FACP from Oregon Health & Science University in Portland acknowledged that heterogeneity was also a barrier to prostate cancer treatment but he felt it would be overcome in this and other genitourinary cancers by using combination targeted therapies just as HIV-AIDS was being beaten by multi-drug approaches. CONTACT: Dr. Tom Powles MBBS, MRCP, MD Barts…

NEW ORLEANSHigh remission rates with extended survival are being achieved in patients who had failed all other therapies including allogeneic stem cell transplantation for their acute lymphoblastic leukemia and otherwise had very short life expectancies. Stephan A Grupp, MD, PhD from the University of Pennsylvania and his colleague Michael Kalos PhD discussed their findings from a study presented here of T-cells engineered with a chimeric antigen receptor (CAR) targeting CD19 (CTL019) which they found to have significant in vivo proliferation, produce complete responses and had long-term persistence without graft versus host disease in children and adults with relapsed, refractory disease.…

LONDON Researchers have shown that endometrial cancer and hopefully ovarian cancer too could potentially be detected much earlier than at present or even prevented altogether by looking for silencing by DNA methylation of the HAND2 gene: an epigenetic process which is not inherited but imposed by the environment to cause cancer. In a study reported in PLoS Medicine (http://www.plosmedicine.org/article/info:doi/10.1371/journal.pmed.1001551) using animal models and tissue samples from patients at University College London Hospital data are presented which promise an era of more individualised therapy thanks to a more complete understanding of the full picture of gene control over cancer which includes…

ORLANDO, FLORIDAPatients receiving radiotherapy for high-risk node-negative prostate cancer benefit as much from 18 months of androgen blockade as from the usual 36 months but have fewer side effects according to study findings announced at the 2013 ASCO Genitourinary Cancers Symposium in Orlando by Dr Abdenour Nabid from Sherbrooke University in Quebec.

SAN FRANCISCONew research has shown the alpha-emitting drug radium 233 to be a benign therapy with no major toxicities while effectively targeting bone metastatic disease and increasing overall survival in patients with castration-resistant prostate cancer whether or not they had received docetaxel therapy. At the ASCO Genitourinary Cancers Symposium Professor Sten Nilsson MD, PhD, a medical oncologist at the Karolinska Institute in Stockholm presented results from the phase III ALSYMPCA study looking at 1.5 year follow up of patients treated with radium compared to those receiving placebo. He discussed his results with AudioMedica.com and assesses the clinical role of this…

SAN FRANCISCO The orally administered androgen receptor blocker enzalutamide significantly extended both overall survival and radiographically determined progression-free survival in men whose metastatic castration-resistant prostate cancer was asymptomatic or mildly symptomatic and had not been treated with chemotherapy in the phase III PREVAIL study. Dr Tomasz Beer MD, FACP, from Oregon Health & Science University in Portland, USA, presented his groups findings to the 2014 ASCO Genitourinary Cancers Symposium from 1717 patients randomised to treatment with enzalutamide or placebo. Overall survival was extended by over two months to a median of 32.4 months while progression free survival went up from…

NEW ORLEANSA new oral tyrosine kinase inhibitor drug idelalisib has proved effective and to have low toxicity in patients with chronic lymphocytic leukaemia (CLL). Richard Furman MD from Weill Cornell Medical College in New York announced findings at the American Society of Hematology Annual Meeting of a phase III, double blind, placebo-controlled study randomising patients to have idelalisib or placebo added to their rituximab treatment. He discussed the clinical implications with AudioMedica.com of the extension of both progression-free and overall survival among patients receiving the new agent in comparison with placebo. Jennifer Brown MD PhD, Director of the Chronic Lymphocytic…

The rare, fatal lympho-proliferative condition: Multicentric Castleman’s Disease MCD could soon be treatable following findings announced at the American Society of Hematology annual meeting in New Orleans. Dr. Raymond S Wong MD, PhD who is a hematology consultant at the Prince of Wales Hospital and The Chinese University of Hong Kong presented data from a multi-national randomized placebo controlled phase 2 study with 79 patients showing remissions in patients treated with the anti-interleukin-6 monoclonal antibody siltuximab. Dr. Wong and Dr. Joseph Mikhael MD, Consultant Hematologist at the Mayo Clinic in Scottsdale Arizona (speaking on behalf of the American Society or…

WASHINGTON DCA new type of immunotherapy has brought responses in children with acute lymphoblastic leukaemia in relapse who had no other options to prevent the progress of this fatal phase of the disease. At the American Association for Cancer Research annual meeting Dr Daniel W. Lee from the Pediatric Oncology Branch of the National Cancer Institute in Bethesda, Maryland, presented findings from his groups study using chimeric antigen receptor T-cell therapy, which involves removing T cells from the child, stimulating and genetically engineering them before re-infusing them in a primed state to fight the cancer. He discusses his findings and…

CAMBRIDGE, UKA new blood test promises quicker assessment of treatment efficacy in patients with metastatic breast cancer. Dr Dana Tsui and colleagues from the Cancer Research UK Cambridge Institute, University of Cambridge, report in the New England Journal of Medicine that circulating tumour DNA is a more powerful marker of breast cancer progression than using blood tests for cancer cells or antigens, and raises the possibility of screening the effectiveness of drugs in days rather than months needed to wait for a change in radiological appearance.

ORLANDO, FLORIDAA decision to delay surgery or radiotherapy for early prostate cancer is in the best interests of most patients according to research presented to the 2013 Genitourinary Cancers Symposium by Dr Andrew Loblaw from the Sunnybrook Health Sciences Centre in Toronto. His groups research has found that the rate of migration of Gleason grade representing disease progression was gradual: accounting for no more than a third of patients developing a form of the disease requiring treatment within ten years. The remaining patients can be spared the side effects of treatment.

ORLANDO, FLORIDAPatients with low-risk prostate cancer are more likely to die with their disease than of it, according to Dr Ayal Aizer from the Brigham and Womens Hospital, the Dana-Farber Cancer Institute and Harvard University in Boston MA a merit-award winner at the American Society of Clinical Oncology (ASCO), American Society for Radiation Oncology (ASTRO) and the Society of Urologic Oncology (SUO) 2013 Genitourinary Cancers Symposium. Treatment with surgery or radiotherapy, he noted, adds toxicity with the potential to do harm without bringing any additional mortality benefit, for the majority of these patients.

3-9-14 9:01am

3-9-14 8:50am

3-7-14 10:54 FLV

3-7-14 3:10pm

In this presentation from “Lymphoma and Myeloma 2015: An International Congress on Hematologic Malignancies”, Dr. Angela Dispenzieri discusses who should be classified as having smoldering myeloma and when is the correct time to treat it.A continuing education program is offered as a supplement to this webcast at the following location:http://elc.imedex.com/ELC/Activity-Search.aspx?search=LM2015EP© 2015 Imedex, LLC.